Cataract Surgery Devices Market Size, Share, Growth, and Industry Analysis, By Types (Intraocular Lens (IOL), Phacoemulsification Equipment), Applications (Hospitals, Ophthalmology Clinics, Ambulatory Surgery Centers), Regional Insights and Forecast to 2035
- Last Updated: 05-November-2026
- Base Year: 2025
- Historical Data: 2021-2024
- Region: Global
- Format: PDF
- Report ID: GGI105751
- SKU ID: 22357093
- Pages: 105
Download FREE Sample
Cataract Surgery Devices Market Size
The Global Cataract Surgery Devices Market size was USD 7320.5 Million in 2025 and is projected to touch USD 7628.62 Million in 2026 and USD 7949.8 Million in 2027, rising to USD 11054.27 Million by 2035, exhibiting a CAGR of 4.21% during the forecast period 2026-2035.
The Cataract Surgery Devices Market is supported by the widespread prevalence of cataracts and the increasing number of surgical procedures performed among aging populations. More than 50% of people over the age of 80 are affected by cataracts, creating sustained demand for surgical equipment and vision-restoration solutions. Intraocular lenses and phacoemulsification equipment collectively account for approximately 75% of device spending, highlighting their central role in cataract treatment. Intraocular lenses restore visual clarity following lens removal, while phacoemulsification systems enable surgeons to remove cataract-affected lenses through minimally invasive techniques. Growing preference for advanced surgical procedures and improved postoperative outcomes is encouraging manufacturers to strengthen their product portfolios. Premium intraocular lens upgrades, including advanced options designed to address different vision requirements, are also increasing the average value per procedure and creating additional opportunities for device manufacturers.
![]()
In the US Cataract Surgery Devices Market, demand is primarily supported by the aging population, increasing cataract treatment volumes, and broad access to health insurance coverage. Ambulatory surgery centers account for nearly 60% of procedures, reflecting the growing preference for outpatient surgical settings that offer efficient treatment and shorter recovery periods. These facilities are creating consistent demand for intraocular lenses, phacoemulsification systems, and related surgical instruments. Premium and toric intraocular lenses are selected in approximately 15% of procedures, contributing to a more specialized product mix and higher-value surgical offerings. Premium lenses address different visual correction requirements, while toric lenses are designed to correct astigmatism alongside cataracts. Growing patient awareness, advances in lens technology, and surgeon preference for customized treatment options are encouraging wider adoption of advanced ophthalmic devices across US surgical facilities.
Key Findings
- Market Size: Starting at $7628.62M in 2026, projected to touch $7949.8M in 2027 to $11054.27M by 2035 at a CAGR of 4.21%.
- Growth Drivers: Population aging lifted cataract procedure volumes by 18%, while premium lens adoption rose 12% among patients seeking reduced spectacle dependence.
- Trends: Femtosecond laser assistance and toric or extended-depth lenses now feature in 20% of procedures, while preloaded delivery systems reached 35% adoption.
- Key Players: Johnson & Johnson, Carl Zeiss Meditec AG, Abbott Laboratories, Alcon-class peers such as STAAR Surgical Company, Glaukos Corporation & more.
- Regional Insights: North America leads with 35% share on premium procedures, Europe holds 28%, Asia-Pacific 29% on rising surgical volumes, and Middle East & Africa 8%.
- Challenges: Surgeon and operating capacity gaps leave 25% of patients in low-income regions untreated, while reimbursement pressure trims premium lens uptake by 10%.
- Industry Impact: Modern cataract surgery restores functional vision in over 95% of cases and shortens procedure time to under 15 minutes.
- Recent Developments: Advanced optic designs raised patient visual satisfaction by 15%, while manufacturing upgrades lifted lens output capacity by about 12%.
The Cataract Surgery Devices Market benefits from the efficiency and consistently high success rates associated with modern cataract procedures. Routine surgeries can typically be completed in under 15 minutes, with success rates exceeding 95% and relatively quick patient recovery. These clinical advantages make treatment accessibility and affordability more influential demand factors than concerns about surgical outcomes. As the aging population grows, healthcare providers are focusing on improving procedure availability, expanding outpatient surgical capacity, and maintaining efficient treatment pathways. This supports continued demand for intraocular lenses, phacoemulsification equipment, and associated surgical instruments.
Patient preferences are also becoming an important competitive factor in the market. Individuals increasingly evaluate intraocular lens options according to lifestyle requirements, including night driving, reading, and reducing dependence on corrective glasses. Approximately 30% of surgeons routinely discuss premium lens options with patients, creating opportunities for manufacturers to differentiate their portfolios beyond standard monofocal lenses. Premium and toric lenses are gaining attention through specialized vision correction capabilities and personalized treatment choices. Consequently, manufacturers are placing greater emphasis on lens innovation, optical performance, and surgeon education to address evolving patient expectations.
![]()
Cataract Surgery Devices Market Trends
Lens technology is the most visible shift in the Cataract Surgery Devices Market. Standard monofocal lenses still dominate volume, yet toric, extended depth of focus and multifocal designs are growing as patients seek independence from glasses, and premium lenses now represent about 20% of procedures in developed markets. Lens makers are refining optical profiles to reduce glare and halos, which were the main complaints about earlier multifocal designs, and satisfaction gains of around 15% are being reported with newer platforms. Preloaded, single-use injector systems are spreading because they cut handling steps and lower contamination risk, and they now appear in roughly 35% of lens implantations.
Surgical technology is also evolving. Phacoemulsification platforms with advanced fluidics and torsional ultrasound reduce energy delivered to the eye, protecting the endothelium and shortening recovery, while femtosecond laser assistance is used in about 10% of procedures where reimbursement or patient payment allows. Integrated imaging and intraoperative guidance help surgeons place toric lenses more accurately, improving refractive outcomes by 10% to 20% in complex cases. Meanwhile, ambulatory surgery centers are standardizing on efficient, compact equipment to raise daily throughput, and high-volume models in India and other emerging markets are producing surgeries at a fraction of the cost per case. Manufacturers that combine reliable equipment, consumables and training are strengthening long-term customer relationships.
Cataract Surgery Devices Market Dynamics
Premium lenses and emerging-market surgical access
Premium lenses carry price points two to four times those of standard lenses, so even a modest rise in uptake, from today's roughly 15% to 20% in developed markets, lifts value per procedure noticeably. Emerging economies provide the largest volume headroom, since cataract surgical rates in several regions remain below 50% of those in high-income countries and a large backlog of untreated patients exists. Government blindness-prevention programs and high-volume surgical centers are bringing costs down, and affordable lens and viscoelastic products tailored to these settings can unlock rapid volume growth. Manufacturers that combine low-cost consumables, surgeon training and equipment financing can build durable positions in markets where the number of operations is expanding fastest.
Aging populations and rising visual expectations
Cataract prevalence rises sharply with age, affecting more than 50% of people above 80, and the global population over 65 is expanding faster than any other group. Surgery has become safer and faster, with success rates above 95%, which encourages earlier intervention as patients no longer wait for severe vision loss. Rising expectations also matter, since people want to keep driving, working and using screens, and demand for premium lenses has grown by about 12% among those seeking less spectacle dependence. Together, demographic pressure and better outcomes keep procedure volumes growing and sustain steady demand for lenses, viscoelastic products and phacoemulsification systems.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Aging population and rising cataract prevalence | High | 2.40% | High | High | High |
| Adoption of premium toric, multifocal and extended-depth lenses | High | 1.90% | High | High | Medium |
| Expansion of surgical access and ambulatory surgery centers | Medium | 1.30% | Medium | High | Medium |
| Technological advances in phacoemulsification and laser-assisted surgery | Medium | 0.95% | Medium | Medium | Medium |
| Government blindness-prevention programs and rising healthcare spending | Low | 0.60% | Low | Medium | Medium |
| Others | Lowest | 0.30% | Low | Low | Low |
| Total Driver Contribution | 7.45% |
RESTRAINTS
"Reimbursement pressure and high premium device cost"
Premium lenses and laser-assisted procedures often require patient co-payments, and in many health systems about 25% of the cost of advanced options is not reimbursed, which holds back uptake among price-sensitive patients. Public payers also push down prices on standard lenses and viscoelastic products, squeezing manufacturer margins by roughly 5% to 10% in competitive tenders. Capital cost is another barrier, since phacoemulsification platforms and femtosecond lasers require sizable investment, and small clinics in developing regions often delay upgrades. Surgeon skill, patient awareness and follow-up care also vary, so market growth depends heavily on healthcare funding and the pace at which affordable technologies reach lower-income settings.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Reimbursement limits and price pressure on lenses and consumables | High | -1.20% | High | Medium | Medium |
| High capital cost of advanced phacoemulsification and laser systems | Medium | -0.85% | Medium | Medium | Low |
| Shortage of trained surgeons and limited access in low-income regions | Low | -0.55% | Medium | Low | Low |
| Others | Lowest | -0.35% | Low | Low | Low |
| Total Restraint Impact | -2.95% |
CHALLENGES
"Surgical capacity gaps and post-operative complications"
Even where devices are available, capacity to perform surgery is limited, and about 25% of patients in low-income regions remain untreated because of shortages of trained ophthalmic surgeons and operating facilities. Complications such as posterior capsule opacification occur in a meaningful share of patients, with rates historically reaching 10% to 20% within a few years, creating follow-up burdens and shaping lens material and edge design choices. Premium lens outcomes also depend on precise patient selection and measurement, and dissatisfaction from visual side effects can discourage uptake. Manufacturers invest heavily in surgeon education, simulation and clinical evidence to manage these risks, but such programs raise costs and extend adoption cycles.
Segmentation Analysis
The Cataract Surgery Devices Market is segmented by product type and by care setting, and the two views show where clinical need meets purchasing. Intraocular lenses, viscoelastic devices and phacoemulsification equipment form the core procedural toolkit, with lenses and equipment accounting for the largest value. By application, hospitals, clinics and ambulatory surgery centers differ in volume, equipment mix and purchasing power, and ambulatory settings handle a growing share of procedures. Understanding how each setting buys consumables versus capital equipment helps suppliers decide where to focus service, financing and training investment.
By Type
Intraocular Lens (IOL)
Intraocular lenses hold about 50% of type-wise demand and are implanted in nearly every cataract operation. Monofocal lenses still represent the majority of volume, while premium toric, multifocal and extended-depth lenses account for roughly 20% of procedures in developed markets and a much larger share of value. Hydrophobic acrylic materials with improved edge design reduce posterior capsule opacification, supporting long-term outcomes and driving replacement of older designs.
Ophthalmic Viscoelastic Device (OVD)
Ophthalmic viscoelastic devices account for roughly 15% of type-wise demand and protect corneal endothelium, maintain chamber space and ease lens insertion. Cohesive, dispersive and viscoadaptive formulations are chosen by surgeons depending on case complexity, and every procedure uses at least one syringe. Because the product is a consumable with predictable use per operation, volumes track surgical numbers closely, and cost-effective formulations are widely used in high-volume centers.
Phacoemulsification Equipment
Phacoemulsification equipment represents about 35% of type-wise demand, covering ultrasound platforms, handpieces, tubing and related consumables. Modern systems offer better fluidics, torsional or micropulse energy and integrated software that lower ultrasound energy by 20% to 40% compared with earlier devices, protecting delicate eye tissue. Disposable packs generate recurring revenue and installed bases anchor long customer relationships, while laser-assisted platforms add a premium tier.
By Application
Hospitals
Hospitals account for about 38% of application demand, handling complex cases, patients with comorbidities and teaching programs. Purchasing is often centralized and tender-based, with emphasis on proven performance, service support and total cost per case. Large hospitals invest in advanced equipment and premium lens programs, and public hospitals in emerging markets deliver high surgical volumes at low cost per procedure.
Ophthalmology Clinics
Ophthalmology clinics represent roughly 27% of application demand, ranging from single-surgeon practices to multi-site networks that perform routine cataract surgery. Many clinics focus on premium lens offerings and patient-paid upgrades, which can lift revenue per case by 20% or more. Consolidation by clinic chains and private equity is raising buying power and standardizing equipment and consumable choices across sites.
Ambulatory Surgery Centers
Ambulatory surgery centers hold about 35% of application demand and are the fastest-expanding setting because they offer lower cost, convenience and efficient turnover. In some developed markets they perform nearly 60% of cataract procedures, with operating times under 15 minutes per case. These centers prioritize compact, reliable equipment, preloaded lens delivery systems and consumable bundles that streamline workflow and reduce inventory.
![]()
Cataract Surgery Devices Market Regional Outlook
Regional demand in the Cataract Surgery Devices Market follows population age structure, healthcare funding and surgical infrastructure. North America holds 35% of global share, Asia-Pacific accounts for 29%, Europe contributes 28% and Middle East & Africa represents 8%, totaling 100%. North America and Europe lead in premium lens and advanced equipment use, while Asia-Pacific delivers the largest growth in procedure volume as access expands. Middle East & Africa is smaller but supported by blindness-prevention programs and private hospital investment. Reimbursement rules and patient willingness to pay strongly shape the product mix in each region.
North America
North America holds 35% of the Cataract Surgery Devices Market, supported by an aging population, broad insurance coverage and high adoption of premium technology. The United States provides about 90% of regional demand, with Canada accounting for most of the remainder. Ambulatory surgery centers perform close to 60% of cataract procedures, and premium and toric lenses are used in roughly 15% to 20% of cases, lifting value per procedure well above global levels. Laser-assisted surgery and advanced imaging are more common here than elsewhere, and surgeons receive extensive training from manufacturers. Medicare and private insurers cover standard lenses, while patients pay out of pocket for many premium upgrades, which makes marketing and patient education important. Consolidation of practices and surgery centers has increased group purchasing, intensifying price negotiations but also creating opportunities for suppliers that offer bundled equipment, consumables and service agreements across large networks.
Europe
Europe accounts for 28% of the Cataract Surgery Devices Market, driven by a large elderly population and well-developed public healthcare systems. Germany, France, the United Kingdom, Italy and Spain together contribute about 65% of regional demand. Surgery rates are high, with several countries performing more than 10,000 cataract operations per million inhabitants each year, and day-case surgery rates exceed 90% in many systems. Public tenders and reimbursement caps place steady downward pressure on lens and viscoelastic prices, while private clinics drive premium lens uptake, which stands at roughly 10% of procedures. Regulatory requirements for medical devices are stringent, raising compliance costs but also reinforcing trust in established brands. Several leading ophthalmic manufacturers are based in the region, supporting strong local research and clinical networks. Waiting-time reduction programs and investment in surgical capacity continue to support procedure volumes across the region.
Asia-Pacific
Asia-Pacific holds 29% of the Cataract Surgery Devices Market and is the largest source of procedure growth, supported by rapidly aging populations in Japan, China and South Korea and large untreated populations in India and Southeast Asia. China and India together account for about 50% of regional demand. Japan has among the highest rates of premium and advanced lens use, while India is known for high-volume, low-cost surgical models that perform operations at a fraction of Western costs. Government blindness-prevention programs, expanding private hospital chains and rising incomes are lifting surgical rates, which in several countries remain below 50% of those in high-income markets. Local manufacturers supply affordable lenses and consumables and hold roughly 30% of regional volume, while international firms lead in premium products and advanced equipment. Training initiatives and equipment financing are central to widening access.
Middle East & Africa
Middle East & Africa represents 8% of the Cataract Surgery Devices Market, with demand concentrated in Gulf countries, Turkey, Egypt, Israel and South Africa. Cataract is a leading cause of blindness across the region, and in parts of Sub-Saharan Africa the surgical rate is less than 20% of what is needed to prevent backlog growth. Gulf nations invest in modern hospitals and attract medical tourism, supporting use of premium lenses and advanced phacoemulsification systems, while public programs and international charities drive volume surgery in lower-income countries. Imports supply more than 80% of devices, so pricing is sensitive to currency swings and procurement cycles. Limited numbers of ophthalmologists and uneven rural access remain barriers, and mobile surgical camps are an important delivery model. Training partnerships, affordable consumables and growing private clinic networks are the key enablers for expansion.
List of Key Cataract Surgery Devices Market Companies Profiled
- Abbott Laboratories
- Novartis AG
- Carl Zeiss Meditec AG
- Essilor International S.A.
- HAAG-Streit Holding AG
- Johnson & Johnson
- Nidek Co., Ltd.
- Topcon Corporation
- Valeant Pharmaceuticals International, Inc.
- Ziemer Ophthalmic Systems AG
- HumanOptics AG
- PhysIOL S.A.
- Calhoun Vision Cente
- EyeKon Medical, Inc.
- Allergan Inc.
- VisionCare Ophthalmic Technologies, Inc.
- Lenstec, Inc.
- STAAR Surgical Company
- Glaukos Corporation
- Sonomed Escalon
Top Companies with Highest Market Share
- Johnson & Johnson: Holds about 22% share, backed by a broad lens, phacoemulsification and viscoelastic portfolio.
- Carl Zeiss Meditec AG: Commands roughly 13% share through surgical microscopes, diagnostics and premium lens offerings.
Investment Analysis and Opportunities
Investment in the Cataract Surgery Devices Market is concentrated on optical innovation, surgical platforms and emerging-market capacity. About 35% of announced spending targets next-generation intraocular lenses with improved depth of focus and reduced visual side effects, since premium products carry the highest margins. Roughly 25% is directed to phacoemulsification and imaging platforms that raise surgical precision and efficiency, while around 20% supports manufacturing expansion in Asia-Pacific to serve rising volumes at lower cost. Acquisitions represent close to 20% of strategic activity as large ophthalmic groups buy specialists in lenses, glaucoma-combined procedures and diagnostics. Opportunity is strongest where surgical rates remain below 50% of developed-market levels and where ambulatory surgery centers are multiplying. Investors also value recurring consumable revenue, because each installed surgical system generates predictable demand for disposable packs and viscoelastic products.
New Products Development
Product development in the Cataract Surgery Devices Market centers on visual quality, convenience and personalization. New intraocular lenses with extended depth of focus and enhanced toric correction aim to reduce glare and halos, and recent designs report patient satisfaction gains of about 15% over earlier multifocal options. Preloaded, single-use injector systems are present in roughly 35% of launches, reducing handling steps and infection risk. Phacoemulsification platforms with improved fluidics and intelligent software lower ultrasound energy use by 20% to 40%, and integrated image guidance supports more accurate toric alignment. Light-adjustable and customizable lens technologies allow vision to be fine-tuned after surgery, while new viscoelastic formulations offer better endothelial protection with easier removal. Combination solutions that pair cataract surgery with minimally invasive glaucoma devices are also advancing.
Recent Developments
- March 2024– Johnson & Johnson expands advanced intraocular lens portfolio: Johnson & Johnson broadened its premium lens range with designs targeting extended depth of focus and reduced visual disturbances, aiming for patient satisfaction improvements of about 15%. The expansion strengthens its position in the premium segment where patient-paid upgrades are growing.
- July 2024– Carl Zeiss Meditec AG enhances cataract workflow and imaging solutions: Carl Zeiss Meditec AG strengthened its cataract surgery workflow with improved intraoperative imaging and lens calculation tools, supporting accuracy gains of roughly 10% to 20% in toric lens alignment. The development helps surgeons deliver more predictable refractive outcomes.
- November 2024– STAAR Surgical Company increases lens manufacturing capacity: STAAR Surgical Company expanded production capability for its implantable lens products, raising output capacity by around 12%. Higher capacity supports growing demand in Asia-Pacific and reduces lead times for customers adopting advanced lens technologies.
- April 2025– Glaukos Corporation advances combined cataract and glaucoma surgical solutions: Glaukos Corporation progressed development of procedures that pair cataract surgery with minimally invasive glaucoma treatment, targeting patients who make up roughly 15% to 20% of the cataract population with coexisting glaucoma. The approach aims to reduce additional surgeries and medication needs.
- September 2025– Topcon Corporation upgrades ophthalmic surgical and diagnostic platforms: Topcon Corporation introduced upgrades to imaging and diagnostic systems used in cataract planning, improving measurement repeatability by about 10%. Better preoperative data supports lens selection accuracy and helps clinics deliver consistent premium lens outcomes.
Report Coverage
This report examines the Cataract Surgery Devices Market through product type, care setting, regional and competitive perspectives, giving decision-makers a structured view of where demand is concentrated and where new growth is emerging. Type coverage includes intraocular lenses at 50%, phacoemulsification equipment at 35% and ophthalmic viscoelastic devices at 15%. Application analysis spans hospitals at 38%, ambulatory surgery centers at 35% and ophthalmology clinics at 27%. The competitive section profiles twenty companies, evaluating lens portfolio depth, surgical platform strength, service reach and innovation focus, and notes that the two leading suppliers together hold about 35% of the market. Supporting analysis addresses drivers, restraints, opportunities and challenges, including cataract prevalence above 50% in people over 80, premium lens use in roughly 20% of developed-market procedures and surgical success rates exceeding 95%.
Cataract Surgery Devices Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 7.75 Billion in 2026 |
|
|
Market Size Value By |
USD 11.21 Billion by 2035 |
|
|
Growth Rate |
CAGR of 4.18% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Cataract Surgery Devices Market expected to touch by 2035?
The global Cataract Surgery Devices Market is expected to reach USD 11.21 Billion by 2035.
-
What CAGR is the Cataract Surgery Devices Market expected to exhibit by 2035?
The Cataract Surgery Devices Market is expected to exhibit a CAGR of 4.18% by 2035.
-
Who are the top players in the Cataract Surgery Devices Market?
Ziemer Ophthalmic Systems AG, Abbott Laboratories, STAAR Surgical Company, Topcon Corporation, Nidek Co. Ltd., HumanOptics AG, EyeKon Medical Inc., Allergan Inc., Essilor International S.A., Valeant Pharmaceuticals International Inc., Lenstec Inc., Novartis AG, PhysIOL S.A., Glaukos Corporation, VisionCare Ophthalmic Technologies Inc., Calhoun Vision Cente, Carl Zeiss Meditec AG, Sonomed Escalon, Johnson & Johnson, HAAG-Streit Holding AG
-
What was the value of the Cataract Surgery Devices Market in 2025?
In 2025, the Cataract Surgery Devices Market value stood at USD 7.44 Billion.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample